ログイン

IMMUNOLOGY & SEROLOGY PROGRESS EXAM

IMMUNOLOGY & SEROLOGY PROGRESS EXAM
45問 • 1年前
  • Yves Laure Pimentel
  • 通報

    問題一覧

  • 1

    False-positive nontreponemal tests for syphilis may occur because of which of the following? * 1/1 Infectious mononucleosis Systemic lupus erythematosus Pregnancy All of these

    All of these

  • 2

    Which test is recommended for testing cerebrospinal fluid for detection of neurosyphilis? * 1/1 RPR VDRL FTA-ABS Enzyme immunoassay

    VDRL

  • 3

    An RPR test done on a 19-year-old woman as part of a prenatal workup was negative but exhibited a rough appearance. What should the technologist do next? * 0/1 Report the result out as negative. Do a VDRL test Send the sample for confirmatory testing. Make serial dilutions and do a titer.

    Make serial dilutions and do a titer.

  • 4

    Suppose an individual develops antibodies in response to a streptococcal pharyngitis infection. This is an example of: * 0/1 Active immunity Passive immunity Adoptive immunity Immunoprophylaxis

    Active immunity

  • 5

    Protection from smallpox could be generated by the transfer of pustular material from cowpox lesion instead of the more hazardous smallpox lesion: * 0/1 Edward Jenner Louis Pasteur Jules Bordet Robert Kaus Correct answer Edward Jenner

    Edward Jenner

  • 6

    What was one of the major contributions of Louis Pasteur to vaccine development? * 0/1 Development of the smallpox vaccine Use of attenuated microorganisms in vaccines Inactivation of bacterial toxins for vaccines Discovery of recombinant vaccine antigens

    Use of attenuated microorganisms in vaccines

  • 7

    The antigenic component of the hepatitis B vaccine differs from those of many of the conventional vaccines in that it consists of a: * 1/1 Live, attenuated virus Inactivated virus Cryptic antigen Recombinant antigen

    Recombinant antigen

  • 8

    Plays an important role in protecting the kidney from damage and in preventing the loss of iron by urinary excretion: * 0/1 Alpha1-antitrypsin Ceruloplasmin Haptoglobin Fibrinogen

    Haptoglobin

  • 9

    Serves to promote aggregation of red blood cells, and increased levels contribute to an increased risk for developing coronary artery disease, especially in women: * 0/1 Alpha1-antitrypsin Ceruloplasmin Haptoglobin Fibrinogen

    Fibrinogen

  • 10

    A deficiency can result in premature emphysema, especially in individuals who smoke or who are exposed to a noxious occupational environment: * 1/1 Alpha1-antitrypsin Ceruloplasmin Haptoglobin Fibrinogen

    Alpha1-antitrypsin

  • 11

    Acute phase reactants elevated up to 1000x in inflammation: * 1/1 CRP and ceruloplasmin CRP and serum amyloid Ceruloplasmin and fibrinogen Ceruloplasmin and haptoglobin

    CRP and serum amyloid

  • 12

    CRP is produced by the: * 1/1 Kidney Liver Bone marrow Thymus

    Liver

  • 13

    All tissue macrophages arise from: * 1/1 B lymphocytes Basophils Neutrophils Monocytes

    Monocytes

  • 14

    Considered the most effective antigen-presenting cells (APCs): * 1/1 T cells Macrophages Neutrophils Dendritic cells

    Dendritic cells

  • 15

    Tissue mast cells resemble: * 1/1 Basophil Eosinophil Monocyte Neutrophil

    Basophil

  • 16

    An immunofluorescence test using reagent antibody directed against the CD3 surface marker would identify which of the following cell types in a sample of human peripheral blood? * 1/1 All mature T lymphocytes T helper lymphocytes only Cytotoxic T lymphocytes only T regulatory cells only

    All mature T lymphocytes

  • 17

    The ability of a single cytokine to alter the expression of several genes is called: * 1/1 Redundancy Pleiotropy Autocrine stimulation Endocrine effect

    Pleiotropy

  • 18

    Indirect immunofluorescence is similar to which type of enzyme immunoassay in terms of the performance of the assay? * 1/1 Competitive Capture ELISA Homogeneous

    ELISA

  • 19

    The positive and negative control values for an ELISA procedure are below their acceptable ranges. What is the most likely cause? * 0/1 Decay of the positive and negative controls Incomplete washing following specimen addition Overly long incubation times Decay of the antibody-enzyme conjugate

    Decay of the antibody-enzyme conjugate

  • 20

    How much diluent needs to be added to 0.2 mL of serum to make a 1:20 dilution? * 1/1 19.8 mL 4.0 mL 3.8 mL 10 mL

    3.8 mL

  • 21

    Which of the following describes the expression of most blood group inheritance? * 1/1 Dominant Recessive Sex-linked Codominant

    Codominant

  • 22

    The anti-G antibody would be negative with which of the following red cell genotypes? * 1/1 Ror rr R2r r'r

    rr

  • 23

    A donor tested D-negative using commercial anti-D reagent. The weak D test was positive. How should the RBC unit be labeled? * 0/1 D-positive D-negative D variant Varies with blood bank policy

    D-positive

  • 24

    Antibodies to the Rh blood group system antigens are usually characterized as: * 0/1 Naturally occurring IgM Immune IgG Immune IgM Naturally occurring IgG and IgM

    Immune IgG

  • 25

    Which of the following antibodies can be neutralized by pooled human urine? * 1/1 Anti-Cs Anti-Sd Anti-Ch Anti-Vel

    Anti-Sd

  • 26

    The procedure that removes intact antibodies from the red cell membranes is: * 1/1 Autoadsorption Neutralization Enzyme pretreatment Elution

    Elution

  • 27

    The removal of an antibody from serum or plasma using the individual’s own red cells is: * 1/1 Autoadsorption Differential adsorption Neutralization Elution

    Autoadsorption

  • 28

    The greatest danger to the fetus (before delivery) affected by HDFN is: * 1/1 Kernicterus Anemia Hyperbilirubinemia Hypertension

    Anemia

  • 29

    The greatest danger to the newborn affected by HDFN is: * 1/1 Kernicterus Anemia Conjugated bilirubin Low L/S ratio

    Kernicterus

  • 30

    The appearance of spherocytes in a baby’s blood smear after delivery is usually associated with: * 0/1 ABO HDFN HDFN caused by anti-D HDFN caused by other IgG antibodies Normal physiologic anemia detected in newborns

    ABO HDFN

  • 31

    Although ABO compatibility is preferred, ABO incompatibility is acceptable for which of the following components? * 0/1 PF24 Cryoprecipitated AHF Apheresis granulocyte Apheresis platelets

    Cryoprecipitated AHF

  • 32

    Which of the following is not a basic component of a QA program? * 0/1 Calibration Preventive maintenance Viral marker testing Record keeping

    Viral marker testing

  • 33

    All blood banks as mandated by law must have a: * 1/1 Water fountain Written laboratory safety program BSC Foot-operated hand wash

    Written laboratory safety program

  • 34

    An ABO discrepancy between forward and reverse grouping owing to weak-reacting or missing antibodies could be BEST explained by which of the following: * 0/1 Patient has a subgroup of blood group A Patient is very old or very young Patient has acquired B phenotype Patient has antibodies to low incidence antigens Patient has antibodies against reagent preservatives

    Patient is very old or very young

  • 35

    Three genes responsible for the production of Rh antigens: * 0/1 RHAG, RH1, and RH2 RHAG, DCE, and dce RHAG, RHD, and RHCE RHD, RHCc, and RHEe RHD, RHCE, and RHce

    RHAG, RHD, and RHCE

  • 36

    Which alloantibody is most likely to be produced if a patient that has the Rh genotype of R1R1 is transfused with red blood cells that have an Rh genotype of R0R0? * 1/1 Anti-D Anti-C Anti-c Anti-E Anti-e

    Anti-c

  • 37

    Anti-G will react with red blood cells of each of the following phenotypes except: * 1/1 D+C- D-C+ D-C- D+C+ rG

    D-C-

  • 38

    If a patient had a positive direct antiglobulin test (DAT) with Anti-IgG, what would happen if you performed a Weak D test on the patient cells? * 0/1 A false-positive result A false-negative result An indeterminate result A valid test result An invalid Rh control test

    A false-positive result

  • 39

    This null produces red blood cells that are resistant to lysis by the addition of 2M Urea, allowing for donor compatibility screening for this phenotype without using antisera. * 0/1 Fy(a-b-) phenotype Le(a-b-) phenotype Lu(a-b-) phenotype Co(a-b-) phenotype Jk(a-b-) phenotype

    Jk(a-b-) phenotype

  • 40

    The rarest of all blood types is characterized by the absence of the common H antigen. This leads to the production of a naturally occurring, hemolytic anti-H. People with this null can only be transfused with red blood cells from other people with this null. * 0/1 McLeod phenotype Bombay phenotype Rhnull phenotype In(Lu)

    Bombay phenotype

  • 41

    Which of the following is associated with HDN? * 0/1 Gerbich Gregory Holley Vel

    Gerbich

  • 42

    If the father of a fetus is Rh positive and the mother is Rh negative, what are the chances that there will be a mother-fetus incompatibility problem? Assume that the couple already had a first child with no medical problems. * 1/1 100% At least 50% Less than 50% 0%

    At least 50%

  • 43

    Antibody potentiators, EXCEPT: * 1/1 LISS PEG Ficin Trypsin

    Trypsin

  • 44

    Immune A and B alloantibodies differ from non-red cell stimulated (naturally occurring) A and B alloantibodies in that the immune antibodies: * 1/1 Are generally IgG rather than IgM Are unable to cross the placenta Can be enhanced in reactivity by incubation at 4C Cause direct agglutination at room temperature Rarely cause clinical hemolysis

    Are generally IgG rather than IgM

  • 45

    A blood donor has the genotype hh, AB. What is his apparent red cell phenotype during routine forward and reverse group typing? * 0/1 A B O AB Cannot be determined

    O

  • other names parasitology

    other names parasitology

    Yves Laure Pimentel · 70問 · 2年前

    other names parasitology

    other names parasitology

    70問 • 2年前
    Yves Laure Pimentel

    PARASITOLOGY

    PARASITOLOGY

    Yves Laure Pimentel · 111問 · 2年前

    PARASITOLOGY

    PARASITOLOGY

    111問 • 2年前
    Yves Laure Pimentel

    HTMLBE

    HTMLBE

    Yves Laure Pimentel · 64問 · 2年前

    HTMLBE

    HTMLBE

    64問 • 2年前
    Yves Laure Pimentel

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    Yves Laure Pimentel · 61問 · 2年前

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    61問 • 2年前
    Yves Laure Pimentel

    HISTOPATHOLOGY

    HISTOPATHOLOGY

    Yves Laure Pimentel · 69問 · 2年前

    HISTOPATHOLOGY

    HISTOPATHOLOGY

    69問 • 2年前
    Yves Laure Pimentel

    CC-2 SPECTROPHOTOMETRY

    CC-2 SPECTROPHOTOMETRY

    Yves Laure Pimentel · 100問 · 2年前

    CC-2 SPECTROPHOTOMETRY

    CC-2 SPECTROPHOTOMETRY

    100問 • 2年前
    Yves Laure Pimentel

    CC-3 ELECTROPHORESIS

    CC-3 ELECTROPHORESIS

    Yves Laure Pimentel · 41問 · 2年前

    CC-3 ELECTROPHORESIS

    CC-3 ELECTROPHORESIS

    41問 • 2年前
    Yves Laure Pimentel

    AUBF LAB SAFETY

    AUBF LAB SAFETY

    Yves Laure Pimentel · 87問 · 2年前

    AUBF LAB SAFETY

    AUBF LAB SAFETY

    87問 • 2年前
    Yves Laure Pimentel

    CSF 1

    CSF 1

    Yves Laure Pimentel · 100問 · 2年前

    CSF 1

    CSF 1

    100問 • 2年前
    Yves Laure Pimentel

    CSF 2

    CSF 2

    Yves Laure Pimentel · 82問 · 2年前

    CSF 2

    CSF 2

    82問 • 2年前
    Yves Laure Pimentel

    SEMEN 1

    SEMEN 1

    Yves Laure Pimentel · 100問 · 2年前

    SEMEN 1

    SEMEN 1

    100問 • 2年前
    Yves Laure Pimentel

    SEMEN 2

    SEMEN 2

    Yves Laure Pimentel · 7問 · 2年前

    SEMEN 2

    SEMEN 2

    7問 • 2年前
    Yves Laure Pimentel

    SYNOVIAL FLUID 1

    SYNOVIAL FLUID 1

    Yves Laure Pimentel · 100問 · 2年前

    SYNOVIAL FLUID 1

    SYNOVIAL FLUID 1

    100問 • 2年前
    Yves Laure Pimentel

    SYNOVIAL FLUID 2

    SYNOVIAL FLUID 2

    Yves Laure Pimentel · 6問 · 2年前

    SYNOVIAL FLUID 2

    SYNOVIAL FLUID 2

    6問 • 2年前
    Yves Laure Pimentel

    SEROUS FLUID

    SEROUS FLUID

    Yves Laure Pimentel · 25問 · 2年前

    SEROUS FLUID

    SEROUS FLUID

    25問 • 2年前
    Yves Laure Pimentel

    PLEURAL FLUID

    PLEURAL FLUID

    Yves Laure Pimentel · 44問 · 2年前

    PLEURAL FLUID

    PLEURAL FLUID

    44問 • 2年前
    Yves Laure Pimentel

    PERICARDIAL FLUID

    PERICARDIAL FLUID

    Yves Laure Pimentel · 18問 · 2年前

    PERICARDIAL FLUID

    PERICARDIAL FLUID

    18問 • 2年前
    Yves Laure Pimentel

    PERITONEAL FLUID/ ASCITIC FLUID

    PERITONEAL FLUID/ ASCITIC FLUID

    Yves Laure Pimentel · 30問 · 2年前

    PERITONEAL FLUID/ ASCITIC FLUID

    PERITONEAL FLUID/ ASCITIC FLUID

    30問 • 2年前
    Yves Laure Pimentel

    AMNIOTIC FLUID

    AMNIOTIC FLUID

    Yves Laure Pimentel · 92問 · 2年前

    AMNIOTIC FLUID

    AMNIOTIC FLUID

    92問 • 2年前
    Yves Laure Pimentel

    FECALYSIS

    FECALYSIS

    Yves Laure Pimentel · 80問 · 2年前

    FECALYSIS

    FECALYSIS

    80問 • 2年前
    Yves Laure Pimentel

    OTHER BODY FLUIDS

    OTHER BODY FLUIDS

    Yves Laure Pimentel · 89問 · 2年前

    OTHER BODY FLUIDS

    OTHER BODY FLUIDS

    89問 • 2年前
    Yves Laure Pimentel

    MTLBE- SUHO NOTES

    MTLBE- SUHO NOTES

    Yves Laure Pimentel · 86問 · 2年前

    MTLBE- SUHO NOTES

    MTLBE- SUHO NOTES

    86問 • 2年前
    Yves Laure Pimentel

    MTLBE..

    MTLBE..

    Yves Laure Pimentel · 35問 · 2年前

    MTLBE..

    MTLBE..

    35問 • 2年前
    Yves Laure Pimentel

    CC- CHROMATOGRAPHY

    CC- CHROMATOGRAPHY

    Yves Laure Pimentel · 19問 · 1年前

    CC- CHROMATOGRAPHY

    CC- CHROMATOGRAPHY

    19問 • 1年前
    Yves Laure Pimentel

    CC-OSMOMETRY

    CC-OSMOMETRY

    Yves Laure Pimentel · 14問 · 1年前

    CC-OSMOMETRY

    CC-OSMOMETRY

    14問 • 1年前
    Yves Laure Pimentel

    CC-ELECTROCHEMISTRY TECHNIQUES

    CC-ELECTROCHEMISTRY TECHNIQUES

    Yves Laure Pimentel · 43問 · 1年前

    CC-ELECTROCHEMISTRY TECHNIQUES

    CC-ELECTROCHEMISTRY TECHNIQUES

    43問 • 1年前
    Yves Laure Pimentel

    CC- CARBOHYDRATES

    CC- CARBOHYDRATES

    Yves Laure Pimentel · 49問 · 2年前

    CC- CARBOHYDRATES

    CC- CARBOHYDRATES

    49問 • 2年前
    Yves Laure Pimentel

    CC- DIABETES MELLITUS

    CC- DIABETES MELLITUS

    Yves Laure Pimentel · 97問 · 2年前

    CC- DIABETES MELLITUS

    CC- DIABETES MELLITUS

    97問 • 2年前
    Yves Laure Pimentel

    MAJOR LIPOPROTEINS

    MAJOR LIPOPROTEINS

    Yves Laure Pimentel · 57問 · 2年前

    MAJOR LIPOPROTEINS

    MAJOR LIPOPROTEINS

    57問 • 2年前
    Yves Laure Pimentel

    MINOR LIPOPROTEINS

    MINOR LIPOPROTEINS

    Yves Laure Pimentel · 63問 · 2年前

    MINOR LIPOPROTEINS

    MINOR LIPOPROTEINS

    63問 • 2年前
    Yves Laure Pimentel

    PROTEINS

    PROTEINS

    Yves Laure Pimentel · 37問 · 2年前

    PROTEINS

    PROTEINS

    37問 • 2年前
    Yves Laure Pimentel

    PLASMA PROTEINS 1

    PLASMA PROTEINS 1

    Yves Laure Pimentel · 91問 · 2年前

    PLASMA PROTEINS 1

    PLASMA PROTEINS 1

    91問 • 2年前
    Yves Laure Pimentel

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    Yves Laure Pimentel · 98問 · 2年前

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    98問 • 2年前
    Yves Laure Pimentel

    MISCELLANEOUS PROTEINS

    MISCELLANEOUS PROTEINS

    Yves Laure Pimentel · 61問 · 2年前

    MISCELLANEOUS PROTEINS

    MISCELLANEOUS PROTEINS

    61問 • 2年前
    Yves Laure Pimentel

    Liver Function Test 1

    Liver Function Test 1

    Yves Laure Pimentel · 100問 · 2年前

    Liver Function Test 1

    Liver Function Test 1

    100問 • 2年前
    Yves Laure Pimentel

    Liver Function Test 2

    Liver Function Test 2

    Yves Laure Pimentel · 96問 · 2年前

    Liver Function Test 2

    Liver Function Test 2

    96問 • 2年前
    Yves Laure Pimentel

    TUMOR MARKERS

    TUMOR MARKERS

    Yves Laure Pimentel · 33問 · 2年前

    TUMOR MARKERS

    TUMOR MARKERS

    33問 • 2年前
    Yves Laure Pimentel

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    Yves Laure Pimentel · 41問 · 2年前

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    41問 • 2年前
    Yves Laure Pimentel

    GLYCOGEN STORAGE DISEASES

    GLYCOGEN STORAGE DISEASES

    Yves Laure Pimentel · 17問 · 2年前

    GLYCOGEN STORAGE DISEASES

    GLYCOGEN STORAGE DISEASES

    17問 • 2年前
    Yves Laure Pimentel

    LIPID STORAGE DISEASES

    LIPID STORAGE DISEASES

    Yves Laure Pimentel · 14問 · 2年前

    LIPID STORAGE DISEASES

    LIPID STORAGE DISEASES

    14問 • 2年前
    Yves Laure Pimentel

    PROTEINS

    PROTEINS

    Yves Laure Pimentel · 71問 · 2年前

    PROTEINS

    PROTEINS

    71問 • 2年前
    Yves Laure Pimentel

    QUICK FIRE- ELECTRODES

    QUICK FIRE- ELECTRODES

    Yves Laure Pimentel · 7問 · 2年前

    QUICK FIRE- ELECTRODES

    QUICK FIRE- ELECTRODES

    7問 • 2年前
    Yves Laure Pimentel

    ELECTROLYTES

    ELECTROLYTES

    Yves Laure Pimentel · 10問 · 2年前

    ELECTROLYTES

    ELECTROLYTES

    10問 • 2年前
    Yves Laure Pimentel

    DRUGS

    DRUGS

    Yves Laure Pimentel · 27問 · 2年前

    DRUGS

    DRUGS

    27問 • 2年前
    Yves Laure Pimentel

    TOXIC AGENTS:

    TOXIC AGENTS:

    Yves Laure Pimentel · 12問 · 2年前

    TOXIC AGENTS:

    TOXIC AGENTS:

    12問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    Yves Laure Pimentel · 100問 · 2年前

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    100問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY (HEMATOPOIESIS 2)

    HEMATOLOGY (HEMATOPOIESIS 2)

    Yves Laure Pimentel · 29問 · 2年前

    HEMATOLOGY (HEMATOPOIESIS 2)

    HEMATOLOGY (HEMATOPOIESIS 2)

    29問 • 2年前
    Yves Laure Pimentel

    hema diseases

    hema diseases

    Yves Laure Pimentel · 25問 · 2年前

    hema diseases

    hema diseases

    25問 • 2年前
    Yves Laure Pimentel

    AML

    AML

    Yves Laure Pimentel · 43問 · 2年前

    AML

    AML

    43問 • 2年前
    Yves Laure Pimentel

    GLOBIN SYNTHESIS

    GLOBIN SYNTHESIS

    Yves Laure Pimentel · 71問 · 2年前

    GLOBIN SYNTHESIS

    GLOBIN SYNTHESIS

    71問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY REFERENCE RANGES

    HEMATOLOGY REFERENCE RANGES

    Yves Laure Pimentel · 31問 · 2年前

    HEMATOLOGY REFERENCE RANGES

    HEMATOLOGY REFERENCE RANGES

    31問 • 2年前
    Yves Laure Pimentel

    DISORDERS OF PRIMARY HEMOSTASIS

    DISORDERS OF PRIMARY HEMOSTASIS

    Yves Laure Pimentel · 34問 · 2年前

    DISORDERS OF PRIMARY HEMOSTASIS

    DISORDERS OF PRIMARY HEMOSTASIS

    34問 • 2年前
    Yves Laure Pimentel

    PLATELET DISORDERS

    PLATELET DISORDERS

    Yves Laure Pimentel · 37問 · 2年前

    PLATELET DISORDERS

    PLATELET DISORDERS

    37問 • 2年前
    Yves Laure Pimentel

    CHARACTERISTICS OF CLOTTING FACTORS

    CHARACTERISTICS OF CLOTTING FACTORS

    Yves Laure Pimentel · 100問 · 2年前

    CHARACTERISTICS OF CLOTTING FACTORS

    CHARACTERISTICS OF CLOTTING FACTORS

    100問 • 2年前
    Yves Laure Pimentel

    4. CLASSIFICATION OF MACROPHAGE

    4. CLASSIFICATION OF MACROPHAGE

    Yves Laure Pimentel · 12問 · 2年前

    4. CLASSIFICATION OF MACROPHAGE

    4. CLASSIFICATION OF MACROPHAGE

    12問 • 2年前
    Yves Laure Pimentel

    3. NATURAL OR INNATE IMMUNITY

    3. NATURAL OR INNATE IMMUNITY

    Yves Laure Pimentel · 39問 · 2年前

    3. NATURAL OR INNATE IMMUNITY

    3. NATURAL OR INNATE IMMUNITY

    39問 • 2年前
    Yves Laure Pimentel

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    Yves Laure Pimentel · 55問 · 2年前

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    55問 • 2年前
    Yves Laure Pimentel

    6. PHAGOCYTOSIS Chemotaxis

    6. PHAGOCYTOSIS Chemotaxis

    Yves Laure Pimentel · 37問 · 2年前

    6. PHAGOCYTOSIS Chemotaxis

    6. PHAGOCYTOSIS Chemotaxis

    37問 • 2年前
    Yves Laure Pimentel

    8. NATURE OF ANTIGEN

    8. NATURE OF ANTIGEN

    Yves Laure Pimentel · 44問 · 2年前

    8. NATURE OF ANTIGEN

    8. NATURE OF ANTIGEN

    44問 • 2年前
    Yves Laure Pimentel

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    Yves Laure Pimentel · 50問 · 2年前

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    50問 • 2年前
    Yves Laure Pimentel

    1. HISTORY

    1. HISTORY

    Yves Laure Pimentel · 69問 · 2年前

    1. HISTORY

    1. HISTORY

    69問 • 2年前
    Yves Laure Pimentel

    2. TYPES OF IMMUNITY

    2. TYPES OF IMMUNITY

    Yves Laure Pimentel · 38問 · 2年前

    2. TYPES OF IMMUNITY

    2. TYPES OF IMMUNITY

    38問 • 2年前
    Yves Laure Pimentel

    7. PHAGOCYTOSIS Engulfment and Digestion

    7. PHAGOCYTOSIS Engulfment and Digestion

    Yves Laure Pimentel · 21問 · 2年前

    7. PHAGOCYTOSIS Engulfment and Digestion

    7. PHAGOCYTOSIS Engulfment and Digestion

    21問 • 2年前
    Yves Laure Pimentel

    8. PHAGOCYTOSIS EXOCYTOSIS

    8. PHAGOCYTOSIS EXOCYTOSIS

    Yves Laure Pimentel · 15問 · 2年前

    8. PHAGOCYTOSIS EXOCYTOSIS

    8. PHAGOCYTOSIS EXOCYTOSIS

    15問 • 2年前
    Yves Laure Pimentel

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    Yves Laure Pimentel · 32問 · 2年前

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    32問 • 2年前
    Yves Laure Pimentel

    11. TRANSPLANTATION IMMUNOLOGY

    11. TRANSPLANTATION IMMUNOLOGY

    Yves Laure Pimentel · 30問 · 2年前

    11. TRANSPLANTATION IMMUNOLOGY

    11. TRANSPLANTATION IMMUNOLOGY

    30問 • 2年前
    Yves Laure Pimentel

    2. LYMPHOID ORGANS

    2. LYMPHOID ORGANS

    Yves Laure Pimentel · 38問 · 2年前

    2. LYMPHOID ORGANS

    2. LYMPHOID ORGANS

    38問 • 2年前
    Yves Laure Pimentel

    3. CLUSTER OF DIFFERENTIATION

    3. CLUSTER OF DIFFERENTIATION

    Yves Laure Pimentel · 48問 · 2年前

    3. CLUSTER OF DIFFERENTIATION

    3. CLUSTER OF DIFFERENTIATION

    48問 • 2年前
    Yves Laure Pimentel

    4. T-CELL DIFFERENTIATION

    4. T-CELL DIFFERENTIATION

    Yves Laure Pimentel · 35問 · 2年前

    4. T-CELL DIFFERENTIATION

    4. T-CELL DIFFERENTIATION

    35問 • 2年前
    Yves Laure Pimentel

    5. T CELL IMMUNODEFICIENCIES

    5. T CELL IMMUNODEFICIENCIES

    Yves Laure Pimentel · 18問 · 2年前

    5. T CELL IMMUNODEFICIENCIES

    5. T CELL IMMUNODEFICIENCIES

    18問 • 2年前
    Yves Laure Pimentel

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    Yves Laure Pimentel · 44問 · 2年前

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    44問 • 2年前
    Yves Laure Pimentel

    7. B CELL IMMUNODEFICIENCIES

    7. B CELL IMMUNODEFICIENCIES

    Yves Laure Pimentel · 23問 · 2年前

    7. B CELL IMMUNODEFICIENCIES

    7. B CELL IMMUNODEFICIENCIES

    23問 • 2年前
    Yves Laure Pimentel

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    Yves Laure Pimentel · 34問 · 2年前

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    34問 • 2年前
    Yves Laure Pimentel

    9. COMPARISON OF T AND B CELLS

    9. COMPARISON OF T AND B CELLS

    Yves Laure Pimentel · 12問 · 2年前

    9. COMPARISON OF T AND B CELLS

    9. COMPARISON OF T AND B CELLS

    12問 • 2年前
    Yves Laure Pimentel

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    Yves Laure Pimentel · 16問 · 2年前

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    16問 • 2年前
    Yves Laure Pimentel

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    Yves Laure Pimentel · 15問 · 2年前

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    15問 • 2年前
    Yves Laure Pimentel

    12. ANTIBODY

    12. ANTIBODY

    Yves Laure Pimentel · 79問 · 2年前

    12. ANTIBODY

    12. ANTIBODY

    79問 • 2年前
    Yves Laure Pimentel

    13. TYPES OF ANTIBODIES

    13. TYPES OF ANTIBODIES

    Yves Laure Pimentel · 97問 · 2年前

    13. TYPES OF ANTIBODIES

    13. TYPES OF ANTIBODIES

    97問 • 2年前
    Yves Laure Pimentel

    14. MONOCLONAL ANTIBODIES

    14. MONOCLONAL ANTIBODIES

    Yves Laure Pimentel · 11問 · 2年前

    14. MONOCLONAL ANTIBODIES

    14. MONOCLONAL ANTIBODIES

    11問 • 2年前
    Yves Laure Pimentel

    1. INTERLEUKINS

    1. INTERLEUKINS

    Yves Laure Pimentel · 23問 · 2年前

    1. INTERLEUKINS

    1. INTERLEUKINS

    23問 • 2年前
    Yves Laure Pimentel

    2. INTERFERONS

    2. INTERFERONS

    Yves Laure Pimentel · 28問 · 2年前

    2. INTERFERONS

    2. INTERFERONS

    28問 • 2年前
    Yves Laure Pimentel

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    Yves Laure Pimentel · 8問 · 2年前

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    8問 • 2年前
    Yves Laure Pimentel

    4. COMPLEMENT SYSTEM

    4. COMPLEMENT SYSTEM

    Yves Laure Pimentel · 19問 · 2年前

    4. COMPLEMENT SYSTEM

    4. COMPLEMENT SYSTEM

    19問 • 2年前
    Yves Laure Pimentel

    15. COMPLEMENT SYSTEM

    15. COMPLEMENT SYSTEM

    Yves Laure Pimentel · 76問 · 2年前

    15. COMPLEMENT SYSTEM

    15. COMPLEMENT SYSTEM

    76問 • 2年前
    Yves Laure Pimentel

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    Yves Laure Pimentel · 21問 · 2年前

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    21問 • 2年前
    Yves Laure Pimentel

    17. COMPLEMENT AND DISEASE STATES

    17. COMPLEMENT AND DISEASE STATES

    Yves Laure Pimentel · 29問 · 2年前

    17. COMPLEMENT AND DISEASE STATES

    17. COMPLEMENT AND DISEASE STATES

    29問 • 2年前
    Yves Laure Pimentel

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    Yves Laure Pimentel · 19問 · 2年前

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    19問 • 2年前
    Yves Laure Pimentel

    19. CYTOKINES

    19. CYTOKINES

    Yves Laure Pimentel · 22問 · 2年前

    19. CYTOKINES

    19. CYTOKINES

    22問 • 2年前
    Yves Laure Pimentel

    20. INTERLEUKINS

    20. INTERLEUKINS

    Yves Laure Pimentel · 24問 · 2年前

    20. INTERLEUKINS

    20. INTERLEUKINS

    24問 • 2年前
    Yves Laure Pimentel

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    Yves Laure Pimentel · 21問 · 2年前

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21問 • 2年前
    Yves Laure Pimentel

    1. SERO

    1. SERO

    Yves Laure Pimentel · 54問 · 2年前

    1. SERO

    1. SERO

    54問 • 2年前
    Yves Laure Pimentel

    2. PRECIPITATION

    2. PRECIPITATION

    Yves Laure Pimentel · 38問 · 2年前

    2. PRECIPITATION

    2. PRECIPITATION

    38問 • 2年前
    Yves Laure Pimentel

    3. PASSIVE IMMUNODIFFUSION

    3. PASSIVE IMMUNODIFFUSION

    Yves Laure Pimentel · 17問 · 2年前

    3. PASSIVE IMMUNODIFFUSION

    3. PASSIVE IMMUNODIFFUSION

    17問 • 2年前
    Yves Laure Pimentel

    4. OUCHTERLONY

    4. OUCHTERLONY

    Yves Laure Pimentel · 15問 · 2年前

    4. OUCHTERLONY

    4. OUCHTERLONY

    15問 • 2年前
    Yves Laure Pimentel

    5. ELECTROPHORETIC TECHNIQUE

    5. ELECTROPHORETIC TECHNIQUE

    Yves Laure Pimentel · 9問 · 2年前

    5. ELECTROPHORETIC TECHNIQUE

    5. ELECTROPHORETIC TECHNIQUE

    9問 • 2年前
    Yves Laure Pimentel

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    Yves Laure Pimentel · 11問 · 2年前

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    11問 • 2年前
    Yves Laure Pimentel

    7. IMMUNOFIXATION ELECTROPHORESIS

    7. IMMUNOFIXATION ELECTROPHORESIS

    Yves Laure Pimentel · 29問 · 2年前

    7. IMMUNOFIXATION ELECTROPHORESIS

    7. IMMUNOFIXATION ELECTROPHORESIS

    29問 • 2年前
    Yves Laure Pimentel

    問題一覧

  • 1

    False-positive nontreponemal tests for syphilis may occur because of which of the following? * 1/1 Infectious mononucleosis Systemic lupus erythematosus Pregnancy All of these

    All of these

  • 2

    Which test is recommended for testing cerebrospinal fluid for detection of neurosyphilis? * 1/1 RPR VDRL FTA-ABS Enzyme immunoassay

    VDRL

  • 3

    An RPR test done on a 19-year-old woman as part of a prenatal workup was negative but exhibited a rough appearance. What should the technologist do next? * 0/1 Report the result out as negative. Do a VDRL test Send the sample for confirmatory testing. Make serial dilutions and do a titer.

    Make serial dilutions and do a titer.

  • 4

    Suppose an individual develops antibodies in response to a streptococcal pharyngitis infection. This is an example of: * 0/1 Active immunity Passive immunity Adoptive immunity Immunoprophylaxis

    Active immunity

  • 5

    Protection from smallpox could be generated by the transfer of pustular material from cowpox lesion instead of the more hazardous smallpox lesion: * 0/1 Edward Jenner Louis Pasteur Jules Bordet Robert Kaus Correct answer Edward Jenner

    Edward Jenner

  • 6

    What was one of the major contributions of Louis Pasteur to vaccine development? * 0/1 Development of the smallpox vaccine Use of attenuated microorganisms in vaccines Inactivation of bacterial toxins for vaccines Discovery of recombinant vaccine antigens

    Use of attenuated microorganisms in vaccines

  • 7

    The antigenic component of the hepatitis B vaccine differs from those of many of the conventional vaccines in that it consists of a: * 1/1 Live, attenuated virus Inactivated virus Cryptic antigen Recombinant antigen

    Recombinant antigen

  • 8

    Plays an important role in protecting the kidney from damage and in preventing the loss of iron by urinary excretion: * 0/1 Alpha1-antitrypsin Ceruloplasmin Haptoglobin Fibrinogen

    Haptoglobin

  • 9

    Serves to promote aggregation of red blood cells, and increased levels contribute to an increased risk for developing coronary artery disease, especially in women: * 0/1 Alpha1-antitrypsin Ceruloplasmin Haptoglobin Fibrinogen

    Fibrinogen

  • 10

    A deficiency can result in premature emphysema, especially in individuals who smoke or who are exposed to a noxious occupational environment: * 1/1 Alpha1-antitrypsin Ceruloplasmin Haptoglobin Fibrinogen

    Alpha1-antitrypsin

  • 11

    Acute phase reactants elevated up to 1000x in inflammation: * 1/1 CRP and ceruloplasmin CRP and serum amyloid Ceruloplasmin and fibrinogen Ceruloplasmin and haptoglobin

    CRP and serum amyloid

  • 12

    CRP is produced by the: * 1/1 Kidney Liver Bone marrow Thymus

    Liver

  • 13

    All tissue macrophages arise from: * 1/1 B lymphocytes Basophils Neutrophils Monocytes

    Monocytes

  • 14

    Considered the most effective antigen-presenting cells (APCs): * 1/1 T cells Macrophages Neutrophils Dendritic cells

    Dendritic cells

  • 15

    Tissue mast cells resemble: * 1/1 Basophil Eosinophil Monocyte Neutrophil

    Basophil

  • 16

    An immunofluorescence test using reagent antibody directed against the CD3 surface marker would identify which of the following cell types in a sample of human peripheral blood? * 1/1 All mature T lymphocytes T helper lymphocytes only Cytotoxic T lymphocytes only T regulatory cells only

    All mature T lymphocytes

  • 17

    The ability of a single cytokine to alter the expression of several genes is called: * 1/1 Redundancy Pleiotropy Autocrine stimulation Endocrine effect

    Pleiotropy

  • 18

    Indirect immunofluorescence is similar to which type of enzyme immunoassay in terms of the performance of the assay? * 1/1 Competitive Capture ELISA Homogeneous

    ELISA

  • 19

    The positive and negative control values for an ELISA procedure are below their acceptable ranges. What is the most likely cause? * 0/1 Decay of the positive and negative controls Incomplete washing following specimen addition Overly long incubation times Decay of the antibody-enzyme conjugate

    Decay of the antibody-enzyme conjugate

  • 20

    How much diluent needs to be added to 0.2 mL of serum to make a 1:20 dilution? * 1/1 19.8 mL 4.0 mL 3.8 mL 10 mL

    3.8 mL

  • 21

    Which of the following describes the expression of most blood group inheritance? * 1/1 Dominant Recessive Sex-linked Codominant

    Codominant

  • 22

    The anti-G antibody would be negative with which of the following red cell genotypes? * 1/1 Ror rr R2r r'r

    rr

  • 23

    A donor tested D-negative using commercial anti-D reagent. The weak D test was positive. How should the RBC unit be labeled? * 0/1 D-positive D-negative D variant Varies with blood bank policy

    D-positive

  • 24

    Antibodies to the Rh blood group system antigens are usually characterized as: * 0/1 Naturally occurring IgM Immune IgG Immune IgM Naturally occurring IgG and IgM

    Immune IgG

  • 25

    Which of the following antibodies can be neutralized by pooled human urine? * 1/1 Anti-Cs Anti-Sd Anti-Ch Anti-Vel

    Anti-Sd

  • 26

    The procedure that removes intact antibodies from the red cell membranes is: * 1/1 Autoadsorption Neutralization Enzyme pretreatment Elution

    Elution

  • 27

    The removal of an antibody from serum or plasma using the individual’s own red cells is: * 1/1 Autoadsorption Differential adsorption Neutralization Elution

    Autoadsorption

  • 28

    The greatest danger to the fetus (before delivery) affected by HDFN is: * 1/1 Kernicterus Anemia Hyperbilirubinemia Hypertension

    Anemia

  • 29

    The greatest danger to the newborn affected by HDFN is: * 1/1 Kernicterus Anemia Conjugated bilirubin Low L/S ratio

    Kernicterus

  • 30

    The appearance of spherocytes in a baby’s blood smear after delivery is usually associated with: * 0/1 ABO HDFN HDFN caused by anti-D HDFN caused by other IgG antibodies Normal physiologic anemia detected in newborns

    ABO HDFN

  • 31

    Although ABO compatibility is preferred, ABO incompatibility is acceptable for which of the following components? * 0/1 PF24 Cryoprecipitated AHF Apheresis granulocyte Apheresis platelets

    Cryoprecipitated AHF

  • 32

    Which of the following is not a basic component of a QA program? * 0/1 Calibration Preventive maintenance Viral marker testing Record keeping

    Viral marker testing

  • 33

    All blood banks as mandated by law must have a: * 1/1 Water fountain Written laboratory safety program BSC Foot-operated hand wash

    Written laboratory safety program

  • 34

    An ABO discrepancy between forward and reverse grouping owing to weak-reacting or missing antibodies could be BEST explained by which of the following: * 0/1 Patient has a subgroup of blood group A Patient is very old or very young Patient has acquired B phenotype Patient has antibodies to low incidence antigens Patient has antibodies against reagent preservatives

    Patient is very old or very young

  • 35

    Three genes responsible for the production of Rh antigens: * 0/1 RHAG, RH1, and RH2 RHAG, DCE, and dce RHAG, RHD, and RHCE RHD, RHCc, and RHEe RHD, RHCE, and RHce

    RHAG, RHD, and RHCE

  • 36

    Which alloantibody is most likely to be produced if a patient that has the Rh genotype of R1R1 is transfused with red blood cells that have an Rh genotype of R0R0? * 1/1 Anti-D Anti-C Anti-c Anti-E Anti-e

    Anti-c

  • 37

    Anti-G will react with red blood cells of each of the following phenotypes except: * 1/1 D+C- D-C+ D-C- D+C+ rG

    D-C-

  • 38

    If a patient had a positive direct antiglobulin test (DAT) with Anti-IgG, what would happen if you performed a Weak D test on the patient cells? * 0/1 A false-positive result A false-negative result An indeterminate result A valid test result An invalid Rh control test

    A false-positive result

  • 39

    This null produces red blood cells that are resistant to lysis by the addition of 2M Urea, allowing for donor compatibility screening for this phenotype without using antisera. * 0/1 Fy(a-b-) phenotype Le(a-b-) phenotype Lu(a-b-) phenotype Co(a-b-) phenotype Jk(a-b-) phenotype

    Jk(a-b-) phenotype

  • 40

    The rarest of all blood types is characterized by the absence of the common H antigen. This leads to the production of a naturally occurring, hemolytic anti-H. People with this null can only be transfused with red blood cells from other people with this null. * 0/1 McLeod phenotype Bombay phenotype Rhnull phenotype In(Lu)

    Bombay phenotype

  • 41

    Which of the following is associated with HDN? * 0/1 Gerbich Gregory Holley Vel

    Gerbich

  • 42

    If the father of a fetus is Rh positive and the mother is Rh negative, what are the chances that there will be a mother-fetus incompatibility problem? Assume that the couple already had a first child with no medical problems. * 1/1 100% At least 50% Less than 50% 0%

    At least 50%

  • 43

    Antibody potentiators, EXCEPT: * 1/1 LISS PEG Ficin Trypsin

    Trypsin

  • 44

    Immune A and B alloantibodies differ from non-red cell stimulated (naturally occurring) A and B alloantibodies in that the immune antibodies: * 1/1 Are generally IgG rather than IgM Are unable to cross the placenta Can be enhanced in reactivity by incubation at 4C Cause direct agglutination at room temperature Rarely cause clinical hemolysis

    Are generally IgG rather than IgM

  • 45

    A blood donor has the genotype hh, AB. What is his apparent red cell phenotype during routine forward and reverse group typing? * 0/1 A B O AB Cannot be determined

    O